Efficiency of gonadotropin-releasing hormone analogue in endometriosis therapy

Abstract

Endometriosis is estrogen- dependent disease. Aromatase P450 is the key enzyme in estrogen biosynthesis. The aim of the study was to compare therapeutic efficiency of gonadotropin-releasing hormone analogue (aGnRH) with ovarian aromatase activity. 64 women with endometriosis were examined after laparoscopic coagulation of endometrioid lesions. The examination included determination of FSH, LH, prolactin, antimüllerian hormone, estradiol, estrone and androstendione by immune-enzyme assay in peripheral blood and determination of ovarian aromatase activity by test with aromatase inhibitor letrozole. Laparoscopic coagulation of endometrioid lesions and following six- month course of aGnRH have lead to decrease of clinical manifestations of the disease and recovery of normal ovulatory menstrual cycle in most (72.5 %) of the patients. Therapeutic efficiency of combined therapy did not depend on basal blood estradiol level and ovarian aromatase activity.

Keywords

endometriosis / ovarian aromatase / GnRH analogues

References

[1] Абашова Е. И. Наружный генитальный эндометриоз и гормональная недостаточность яичников. Автореф. дис… канд. мед. наук. СПб., 1999.

[2] Денисова В. М., Потин В. В., Ярмолинская М. И., Тимофеева Е. М. Активность овариальной ароматазы при эндометриозе // Журнал акушерства и женских болезней. — 2013. — Т. LXII (2). — С. 17–22.

[3] Молотков А. С., Ярмолинская М. И., Полякова В. О. с соавт. Значение экспрессии ароматазы в патогенезе наружного генитального эндометриоза // Молекулярная медицина. — 2012. — Т. 4. — С. 41–44.

[4] Савина В. А. Роль ароматазы Р450 в патогенезе синдрома поликистозных яичников // Автореф. дис… канд. мед. наук. — СПб., 2012.

[5] Ярмолинская М. И. Генитальный эндометриоз: влияние гормональных, иммунологических и генетических факторов на развитие, особенности течения и выбор терапии // Автореф. дис… д-ра мед. наук. — СПб., 2009.

[6] American Fertility Society. Revised American Fertility Society Classification of Endometriosis // Fertil. Steril. — 1985. — Vol. 43. — P. 347–350.

[7] Bilotas M., Baranão R. I., Buquet R. et al. Effect of GnRH analogues on apoptosis and expression of Bcl-2, Bax, Fas and FasL proteins in endometrial epithelial cell cultures from patients with endometriosis and controls // Hum. Reprod. — 2007. — Vol. 22. — P. 644–653.

[8] Fleming R., Kelsey T. W., Anderson R. A. et al. Interpreting human follicular recruitment and antimüllerian hormone concentrations throughout life // Fertil. Steril. — 2012. — Vol. 98. — P. 1097–1102.

[9] Harrison G. S., Wierman M. E., Nett T. M. et al. Gonadotropin-releasing hormone and its receptor in normal and malignant cells // Endocrine-Related Cancer. — 2004. — Vol. 11. — P. 725–648.

[10] Hugues J.-N., Durnerin E. C. Revisiting gonadotropin-releasing hormone agonist protocols and management of poor ovarian responses to gonadotrophins // Human Reproduction Update. — 1998. — Vol. 4 (1). — P. 83–101.

[11] Limonta P., Moretti R. M., Marelli M. M. et al. The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway // Endocrinology. — 1999. — Vol. 140. — P. 5250–5256.

[12] Luo X., Xu J. Chegini N. Gonadotropin releasing hormone analogue (GnRHa) alters the expression and activation of Smad in human endometrial epithelial and stromal cells // Reproductive Biology and Endocrinology. — 2003. — Vol. 1. — P. 125, http://www.rbej.com/connect/1/1/125.

[13] Meresman G. F., Biotas M.A, Lombardi E. et al. Effect of GnRH analogues on apoptosis and release of interleukin-1β and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis // Human Reproduction. — 2003. — Vol. 18 (9). — P. 1767–1771.

[14] Millar R. P., Lu Z. I., Flanagan C. A. et al. Gonadotropin-releasing hormone receptors // Endocrin. Rev. — 2004. — Vol. 25. — P. 235–275.

[15] Olive D. L. Gonadotropin-Releasing Hormone Agonists for Endometriosis // N. Engl. J. Med. — 2008. — Vol. 359. — P. 1136–1142.

[16] Visser J. A., Schipper I., Laven J. S. E. et al. Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency // Nat. Rev. Endocrinol. — 2012. — Vol. 8 (6). — P. 331–41.

[17] Wilson A. C., S. V. Meethal S. V., Bowen R. L., Atwood C. S. Leuprolide acetate: a drug of diverse clinical applications // Expert Opin. Investig. Drugs. — 2007. — Vol. 16 (11). — P. 1–13.

RIGHTS & PERMISSIONS

Denisova V.M.